Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 23, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
On September 22, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 12,884 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on September 23, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Investor Verification Points
- Verify the total number of shares transferred (12,884) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the role of Abacus (GSK) Trustees Limited as the trustee for the GSK Trust.
- Note that Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.
- Understand that this filing does not contain financial performance data for the period.